Physician profile
Alan Klibanoff
NPI 1740238989
$7,274.60
in general payments reported to CMS, 2019-2025
27 companies · $56.19 in 2025
The $56.19 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $930 · 2021: $1,402 · 2022: $1,467 · 2023: $967 · 2024: $1,023 · 2025: $56.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.45 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,962.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,435.32 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $769.45 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $738.97 | 2019-2024 | Simponi, Simponi Aria, Remicade |
| Gilead Sciences, INC. | $420.55 | 2019-2024 | |
| Pfizer INC. | $323.14 | 2019-2024 | |
| Celgene Corporation | $318.92 | 2021-2024 | Zeposia |
| Genzyme Corporation | $229.41 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $187.09 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $162.41 | 2020-2022 | |
| Allergan, INC. | $128.10 | 2019-2020 | |
| Vivus LLC | $110.53 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $100.91 | 2019-2020 | |
| Lilly USA, LLC | $59.74 | 2023-2024 | Omvoh |
| Redhill Biopharma INC. | $48.63 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $40.29 | 2019-2024 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $38.52 | 2021-2023 | |
| Ucb, INC. | $36.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.88 | 2020 | |
| Celltrion USA INC. | $25.41 | 2024 | Zymfentra |
| Fresenius Kabi USA, LLC | $21.24 | 2023 | Idacio |
| Shield Therapeutics INC | $18.69 | 2024 | |
| Shire North American Group INC | $17.67 | 2019 | |
| Covidien LP | $15.85 | 2019 | |
| Alfasigma USA, INC. | $14.94 | 2020 | |
| Ardelyx, INC. | $12.19 | 2022 | |
| Ethicon US, LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Klibanoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.